Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

The demand for glucagon-like peptide 1 (GLP-1s) receptor agonists for overweight/obesity has created a clinical conundrum for ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, ...

Mounjaro is approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...